EUVIMEDEUVIMED entdecken
Crossref

Tenofovir exerts antiviral effects in pregnant women with chronic hepatitis B by influencing the expression of miR ‐21‐5p

Lei Zhang, Juan Du, Lan Shao, Cuili Yang, Yu Wang, Zhongfu Mo, Jinyu Gu iD

Journal of Obstetrics and Gynaecology Research · 2025

DOI: 10.1111/jog.16355 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Obstetrics and Gynaecology Research, 2025. Verfasst von Lei Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Shijiazhuang Maternal and Child Health Hospital, Shijiazhuang, China. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, MicroRNAs, Tenofovir, Antiviral Agents. Die Arbeit nennt 36 Literaturangaben. Gefördert von: Hebei Provincial Health Care Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

In pregnant women with chronic hepatitis B (CHB), tenofovir (TDF) has demonstrated significant efficacy in disrupting the replication of the hepatitis B virus (HBV) and in preventing mother‐to‐child transmission (MTCT). This study seeks to elucidate the role of miR‐21‐5p in mediating the antiviral effect of TDF.

Methods

Initially, the levels of miR‐21‐5p in pregnant women with and without CHB were compared by RT‐qPCR assay. Subsequently, a comparison was made between the levels of HBV and miR‐21‐5p prior to and following treatment with TDF. Moreover, the correlation between miR‐21‐5p levels and HBV DNA, HBsAg or HBeAg was analyzed by Pearson correlation analysis. Lastly, HBV‐infected huh‐7 cells were cultured in vitro. Then, RT‐qPCR and ELISA assays were conducted to investigate the influence of modulating miR‐21‐5p levels on HBV replication. Results miR‐21‐5p levels were significantly increased in CHB pregnant women. Following treatment with TDF, HBV was effectively controlled. More crucially, TDF led to a reduction in miR‐21‐5p levels. The level of miR‐21‐5p exhibited a positive correlation with HBV DNA, HBsAg and HBeAg. In cell experiments, the inhibition of miR‐21‐5p resulted in a significant decrease in levels of HBV DNA, HBsAg, and HBeAg. Conversely, overexpression of miR‐21‐5p yielded opposing results.

Conclusion

In pregnant women with CHB, TDF may inhibit HBV replication by inhibiting the expression of miR‐21‐5p. This mechanism contributes to the mitigation of infection exacerbation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B, ChronicMicroRNAsTenofovirAntiviral AgentsPregnancy Complications, InfectiousHumansFemalePregnancyAdultHepatitis B virusVirus ReplicationHepatitis B e AntigensDNA, Viral

Stichwörter der Autor:innen

HBV replicationantiviralchronic hepatitis BmiR‐21‐5ppregnant womentenofovir

Substanzen

MicroRNAsTenofovirAntiviral AgentsMIRN21 microRNA, humanHepatitis B e AntigensDNA, Viral

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Shijiazhuang Maternal and Child Health Hospital, Shijiazhuang, China.

ORCID-Profile: Jinyu Gu

Förderung

  • Hebei Provincial Health Care Commission

Zitieren

APA

Zhang, L., Du, J., Shao, L., Yang, C., Wang, Y., Mo, Z., & Gu, J. (2025). Tenofovir exerts antiviral effects in pregnant women with chronic hepatitis B by influencing the expression of miR ‐21‐5p. Journal of Obstetrics and Gynaecology Research. https://doi.org/10.1111/jog.16355

Vancouver

Zhang L, Du J, Shao L, Yang C, Wang Y, Mo Z, et al. Tenofovir exerts antiviral effects in pregnant women with chronic hepatitis B by influencing the expression of miR ‐21‐5p. Journal of Obstetrics and Gynaecology Research. 2025. doi:10.1111/jog.16355

BibTeX
@article{Zhang2025,
  author = {Zhang, Lei and Du, Juan and Shao, Lan and Yang, Cuili and Wang, Yu and Mo, Zhongfu and Gu, Jinyu},
  title = {Tenofovir exerts antiviral effects in pregnant women with chronic hepatitis B by influencing the expression of miR ‐21‐5p},
  journal = {Journal of Obstetrics and Gynaecology Research},
  year = {2025},
  doi = {10.1111/jog.16355}
}
Kostenlos starten →